GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » Cash Flow from Investing

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Cash Flow from Investing : $0.26 Mil (TTM As of Sep. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Eloxx Pharmaceuticals Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2023, Eloxx Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.23 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Eloxx Pharmaceuticals gained $0.23 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2023.


Eloxx Pharmaceuticals Cash Flow from Investing Historical Data

The historical data trend for Eloxx Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eloxx Pharmaceuticals Cash Flow from Investing Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 -33.52 33.79 2.06 -0.07

Eloxx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 - 0.01 0.01 0.23

Eloxx Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Eloxx Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Eloxx Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Sep. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eloxx Pharmaceuticals  (OTCPK:ELOX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Eloxx Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means Eloxx Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Eloxx Pharmaceuticals's sale of property, plant, equipment for the three months ended in Sep. 2023 was $0.23 Mil. It means Eloxx Pharmaceuticals gained $0.23 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Eloxx Pharmaceuticals's purchase of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Eloxx Pharmaceuticals spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Eloxx Pharmaceuticals's sale of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Eloxx Pharmaceuticals gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Eloxx Pharmaceuticals's purchase of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Eloxx Pharmaceuticals spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Eloxx Pharmaceuticals's sale of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Eloxx Pharmaceuticals gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Eloxx Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Sep. 2023 was $0.00 Mil. It means Eloxx Pharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Eloxx Pharmaceuticals's cash from discontinued investing activities for the three months ended in Sep. 2023 was 0.00 Mil. It means Eloxx Pharmaceuticals paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Eloxx Pharmaceuticals's cash from other investing activities for the three months ended in Sep. 2023 was $0.00 Mil. It means Eloxx Pharmaceuticals paid $0.00 Mil for other investing activities.


Eloxx Pharmaceuticals Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Watertown, MA, USA, 02472
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Executives
Sumit Aggarwal director, officer: PRESIDENT AND CEO 480 ARSENAL WAY, WATERTOWN MA 02472
Vijay Modur officer: HEAD OF R&D C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451
Lindsay Androski director C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Gadi Veinrib director 12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Jasbir Seehra director C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Zafrira Avnur director 210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467
Alan Edmund Walts director 197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Pontifax Iv Gp L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax Management 4 G.p. (2015) Ltd. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (israel) Iv, L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (china) Iv L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (cayman) Iv L.p. 10 percent owner 4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Headlines

From GuruFocus

Eloxx Pharmaceuticals Announces Changes to Board of Directors

By PurpleRose PurpleRose 07-15-2022

Eloxx Pharmaceuticals Announces Changes to Board of Directors

By GuruFocusNews GuruFocusNews 07-05-2022